HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Endomyocardial disease — Clinical Guidelines

Overview

Endomyocardial disease encompasses a spectrum of conditions characterized by fibrotic or thrombotic lesions within the myocardium, often associated with eosinophilia. It can manifest as restrictive cardiomyopathy with features like endomyocardial fibrosis and can be idiopathic or secondary to conditions like hypereosinophilic syndrome or malignancies 1 4 5.

Diagnosis

Clinical Presentation: Heart failure, often with mitral regurgitation, and evidence of eosinophilia 7 5.

Imaging Techniques:

- Cardiac MRI: Useful for detecting thrombus, endomyocardial fibrosis, and inflammation 1. - Echocardiography: Identifies apical obliteration, increased endocardial reflectivity, and biventricular involvement 6 8.

Pathological Confirmation: Histological examination of myocardial tissue for fibrotic lesions, necrosis, and eosinophil infiltration 5 10.

Molecular Diagnostics: Polymerase chain reaction (PCR) for viral etiologies in suspected cases 2.

Management

Surgical Intervention: Indicated for severe biventricular fibrosis and refractory heart failure 3 9.

Medical Management:

- Eosinophil Targeting: Treatment of underlying causes (e.g., malignancy, parasitic infections) and use of corticosteroids or other anti-eosinophil therapies 4 10. - Heart Failure Support: Diuretics, ACE inhibitors, and beta-blockers to manage symptoms and improve cardiac function 11.

Monitoring: Regular echocardiograms and cardiac MRI to assess disease progression and response to therapy 1 6.

Special Populations

Pediatrics: Left ventricular function is crucial for prognosis; hemodynamic monitoring and early intervention are essential 11.

Pregnancy: Limited data; fetal echocardiography and close monitoring for hydrops fetalis and endomyocardial involvement are critical 2.

Comorbidities: Presence of eosinophilia from various causes necessitates comprehensive evaluation and management of the underlying condition 4 10.

Key Recommendations

Utilize cardiac MRI and echocardiography for accurate diagnosis and monitoring of endomyocardial disease progression (Evidence: Moderate) 1 6.

Consider surgical intervention for patients with severe biventricular fibrosis and refractory heart failure (Evidence: Weak) 3 9.

Address underlying causes of eosinophilia and manage heart failure symptoms with appropriate pharmacological agents (Evidence: Moderate) 4 11.

Closely monitor pediatric patients focusing on left ventricular function for better prognostic outcomes (Evidence: Moderate) 11.

In pregnant women, employ fetal echocardiography and PCR for viral etiologies in suspected cases of endomyocardial disease (Evidence: Weak) 2.

References

1 Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. International journal of cardiology 2008. link 2 Oyer CE, Ongcapin EH, Ni J, Bowles NE, Towbin JA. Fatal intrauterine adenoviral endomyocarditis with aortic and pulmonary valve stenosis: diagnosis by polymerase chain reaction. Human pathology 2000. link 3 Arvay A, Lengyel M, Mészáros R, Palik I. Surgical experience with thrombotic and fibrotic forms of non-tropical eosinophilic endomyocardial disease. The Thoracic and cardiovascular surgeon 1985. link 4 Spry CJ, Tai PC, Davies J. The cardiotoxicity of eosinophils. Postgraduate medical journal 1983. link 5 Davies J, Spry CJ, Sapsford R, Olsen EG, de Perez G, Oakley CM et al.. Cardiovascular features of 11 patients with eosinophilic endomyocardial disease. The Quarterly journal of medicine 1983. link 6 Acquatella H. Two-dimensional echocardiography in endomyocardial disease. Postgraduate medical journal 1983. link 7 Puigbo JJ, Combellas I, Acquatella H, Marsiglia I, Tortoledo F, Casal H et al.. Endomyocardial disease in South America--report on 23 cases in Venezuela. Postgraduate medical journal 1983. link 8 Davies J, Gibson DG, Foale R, Heer K, Spry CJ, Oakley CM et al.. Echocardiographic features of eosinophilic endomyocardial disease. British heart journal 1982. link 9 Davies J, Sapsford R, Brooksby I, Olsen EG, Spry CJ, Oakley CM et al.. Successful surgical treatment of two patients with eosinophilic endomyocardial disease. British heart journal 1981. link 10 Jaski BE, Goetzl EJ, Said JW, Fishbein MC. Endomyocardial disease and eosinophilia. Report of a case. Circulation 1978. link 11 Krovetz LJ, Maron BJ, Morse A, Brown H, Goldbloom SD. Prognostic implications of left ventricular function in endomyocardial disease in infants and children. The Journal of pediatrics 1975. link80641-x)

Endomyocardial disease